Please login to the form below

Not currently logged in
Email:
Password:

AlixPartners appoints new managing director

Dr Andreas Vogt takes up new role at the global business advisory firm

Dr Andreas VogtDr Andreas Vogt has joined AlixPartners' healthcare and life sciences team in a Zurich-based role that focuses on supporting medtech and healthcare companies through performance improvement and large transformational projects.

Previously healthcare and life sciences partner at Deloitte Consulting, Vogt has experience advising companies in the medtech, healthcare and pharmaceutical industries in implementing and improving strategies.

Simon Freakley, CEO at AlixPartners, said: “He has substantial experience in this industry, both as a strategy consultant and as a physician, and I am confident that his expertise will prove invaluable as we continue to strengthen our European healthcare and life sciences practice.”

Prior to his experience at Deloitte Consulting, Vogt served Roland Berger Strategy Consultants as a member of the management team.

Beatrix Moarth, managing director and country head for Switzerland at AlixPartners, said: “He has worked in a variety of consulting positions and has an excellent network.

“I am confident that Andreas will be an integral part in supporting clients within the healthcare and life sciences field of business as we continue to grow.”

23rd March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics